{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:38:43Z","timestamp":1788219523243,"version":"build-2803163510"},"reference-count":200,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.arbres.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:46:24Z","timestamp":1777045584000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Biologics Administered for Severe Asthma on T2-comorbidities: A Narrative Review"],"prefix":"10.1016","author":[{"given":"Angelica","family":"Tiotiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Guidos Fogelbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herberto Jose","family":"Chong-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plamena","family":"Novakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denislava","family":"Nedeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Steiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2026.04.008_bib1000","unstructured":"Global Initiative for Asthma \u2013 GINA. Availble from: https:\/\/ginasthma.org\/2025-gina-severe-asthma-guide\/. [Accessed 1 October 2025]."},{"key":"10.1016\/j.arbres.2026.04.008_bib1005","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1010","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.alit.2016.04.011","article-title":"Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine","volume":"65","author":"Agache","year":"2016","journal-title":"Allergol Int"},{"issue":"11","key":"10.1016\/j.arbres.2026.04.008_bib1025","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/all.15889","article-title":"Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","article-title":"Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry","volume":"132","author":"Scelo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","article-title":"Association between T2-related comorbidities and effectiveness of biologics in severe asthma","volume":"209","author":"Wechsler","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1040","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1183\/13993003.01141-2016","article-title":"Excess medical costs in patients with asthma and the role of comorbidity","volume":"48","author":"Chen","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.04.008_bib1045","unstructured":"Global Initiative for Asthma \u2013 GINA. Available from: https:\/\/ginasthma.org\/2025-gina-strategy-report\/. [Accessed 13 Nove 2025]."},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1055","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.arbres.2026.04.008_bib1060","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"issue":"10086","key":"10.1016\/j.arbres.2026.04.008_bib1065","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2026.04.008_bib1070","doi-asserted-by":"crossref","first-page":"107979","DOI":"10.1016\/j.rmed.2025.107979","article-title":"Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps","volume":"238","author":"Tiotiu","year":"2025","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1075","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1080","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/17476348.2021.1932470","article-title":"Management of adult asthma and chronic rhinitis as one airway disease","volume":"15","author":"Tiotiu","year":"2021","journal-title":"Expert Rev Respir Med"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/17476348.2023.2262920","article-title":"Epithelial alarmins: a new target to treat chronic respiratory diseases","volume":"17","author":"Nedeva","year":"2023","journal-title":"Expert Rev Respir Med"},{"issue":"Suppl. 1","key":"10.1016\/j.arbres.2026.04.008_bib1090","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2466-6-S1-S3","article-title":"Survey on the impact of comorbid allergic rhinitis in patients with asthma","volume":"6","author":"Valovirta","year":"2006","journal-title":"BMC Pulm Med"},{"issue":"150","key":"10.1016\/j.arbres.2026.04.008_bib1095","doi-asserted-by":"crossref","first-page":"180056","DOI":"10.1183\/16000617.0056-2018","article-title":"Current opinions for the management of asthma associated with ear, nose and throat comorbidities","volume":"27","author":"Tiotiu","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1398-9995.2006.01007.x","article-title":"Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial","volume":"61","author":"Price","year":"2006","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2020.05.026","article-title":"Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis","volume":"125","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"Adelroth","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"10.1016\/j.arbres.2026.04.008_bib1115","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1125","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1130","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1135","doi-asserted-by":"crossref","first-page":"e12094","DOI":"10.1002\/clt2.12094","article-title":"Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.arbres.2026.04.008_bib1140","doi-asserted-by":"crossref","first-page":"913424","DOI":"10.3389\/fimmu.2022.913424","article-title":"Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2026.04.008_bib1145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/JAA.S288952","article-title":"Effectiveness and response predictors of omalizumab in treating patients with seasonal allergic rhinitis: a real-world study","volume":"14","author":"Ma","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","article-title":"Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma","volume":"39","author":"Kopp","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"24","key":"10.1016\/j.arbres.2026.04.008_bib1155","first-page":"5249","article-title":"Effects of omalizumab therapy on allergic rhinitis: a pilot study","volume":"20","author":"Masieri","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.arbres.2026.04.008_bib1160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.imlet.2020.08.002","article-title":"Long-term omalizumab efficacy in allergic rhinitis","volume":"227","author":"Cavaliere","year":"2020","journal-title":"Immunol Lett"},{"issue":"8","key":"10.1016\/j.arbres.2026.04.008_bib1165","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1170","first-page":"501","article-title":"Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis","volume":"59","author":"Tsabouri","year":"2021","journal-title":"Rhinology"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1175","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1945892419884774","article-title":"Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Yu","year":"2020","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.arbres.2026.04.008_bib1180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/ALX02205E","article-title":"Anti-IgE: A treatment option in allergic rhinitis?","volume":"5","author":"Pfaar","year":"2021","journal-title":"Allergol Sel"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1185","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/all.16001","article-title":"Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy","volume":"79","author":"Wipperman","year":"2024","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.04.008_bib1195","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/JAA.S318892","article-title":"Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial","volume":"14","author":"Corren","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1200","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.alit.2022.05.010","article-title":"Efficacy of a house dust mite sublingual immunotherapy tablet as add-on dupilumab in asthma with rhinitis","volume":"71","author":"Hoshino","year":"2022","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1210","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s12325-024-02889-8","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma across multiple clinically relevant subgroups in the NAVIGATOR study","volume":"41","author":"Carr","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1215","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","article-title":"Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions","volume":"22","author":"Gibson","year":"2021","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1220","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jaci.2020.11.037","article-title":"Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps","volume":"147","author":"Klingler","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1225","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1235","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1240","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/00034894251344426","article-title":"Omalizumab efficacy in chronic rhinosinusitis patients with recurrent nasal polyps: an open-label, single-center, randomized, controlled study","volume":"134","author":"Noeiaghdam","year":"2025","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1245","doi-asserted-by":"crossref","first-page":"e047344","DOI":"10.1136\/bmjopen-2020-047344","article-title":"Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1250","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/all.16499","article-title":"Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence","volume":"80","author":"Cai","year":"2025","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1260","doi-asserted-by":"crossref","first-page":"100702","DOI":"10.1016\/j.waojou.2022.100702","article-title":"Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers \u2013 a real-life prospective study","volume":"15","author":"Zheng","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18176\/jiaci.0391","article-title":"Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study","volume":"30","author":"Tiotiu","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1270","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11882-023-01106-w","article-title":"Omalizumab treatment in uncontrolled asthma and CRSwNP patients, with previous endoscopic sinus surgery, to improve quality of life and endoscopic outcomes: a two-year real-life study","volume":"23","author":"Maza-Solano","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1275","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together \u2013 a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinology"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1280","first-page":"245","article-title":"The efficacy of omalizumab in patients with chronic rhinosinusitis with nasal polyps and comorbid severe allergic asthma","volume":"23","author":"Atayik","year":"2024","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1285","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1290","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1295","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15434","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis","volume":"78","author":"Fokkens","year":"2023","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.arbres.2026.04.008_bib1300","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.jaip.2023.08.015","article-title":"Mepolizumab reduces systemic corticosteroid use in chronic rhinosinusitis with nasal polyps","volume":"11","author":"Chupp","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1305","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1310","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00405-024-08903-7","article-title":"Efficacy of different biologics for treating chronic rhinosinusitis with nasal polyps: a network meta-analysis","volume":"282","author":"Wang","year":"2025","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1315","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.18176\/jiaci.0905","article-title":"REDES study: mepolizumab is effective in patients with severe asthma and comorbid nasal polyps","volume":"33","author":"Arismendi","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/biomedicines11020485","article-title":"Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dom\u00ednguez-Sosa","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.arbres.2026.04.008_bib1330","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"issue":"8","key":"10.1016\/j.arbres.2026.04.008_bib1335","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/jpm12081304","article-title":"Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a multicentric real-life study","volume":"12","author":"Gallo","year":"2022","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1340","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12016-022-08938-w","article-title":"Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps","volume":"64","author":"Tiotiu","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1345","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1350","first-page":"37","article-title":"Improvement in olfaction in patients with CRSwNP and severe asthma taking anti-IgE and anti-IL-5 biologics: a real-life study","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1360","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1365","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.3390\/jcm13103013","article-title":"Unlocking the long-term effectiveness of benralizumab in severe eosinophilic asthma: a three-year real-life study","volume":"13","author":"Pini","year":"2024","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1370","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"14","key":"10.1016\/j.arbres.2026.04.008_bib1375","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.3390\/jcm13144247","article-title":"Real-life clinical outcomes of benralizumab treatment in patients with uncontrolled severe asthma and coexisting chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Chiner","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2026.04.008_bib1380","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2026.04.008_bib1385","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/JAA.S437190","article-title":"Benralizumab in severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: the real-world, multi-country RANS observational study","volume":"17","author":"Le","year":"2024","journal-title":"J Asthma Allergy"},{"issue":"8","key":"10.1016\/j.arbres.2026.04.008_bib1390","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/alr.22774","article-title":"Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: a real-world study","volume":"11","author":"Bajpai","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"10209","key":"10.1016\/j.arbres.2026.04.008_bib1395","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1400","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/all.15222","article-title":"Dupilumab improves health related quality of life: results from the phase 3 SINUS studies","volume":"77","author":"Lee","year":"2022","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1405","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaip.2021.09.037","article-title":"Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1410","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinology"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1415","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/19458924251313493","article-title":"Long-term effectiveness of dupilumab in severe uncontrolled chronic rhinosinusitis with nasal polyps: a multicenter retrospective study","volume":"39","author":"Russo","year":"2025","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1420","doi-asserted-by":"crossref","first-page":"104106","DOI":"10.1016\/j.amjoto.2023.104106","article-title":"Dupilumab in chronic rhinosinusitis with nasal polyps: real life data in a multicentric Sicilian experience","volume":"45","author":"Galletti","year":"2024","journal-title":"Am J Otolaryngol"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1425","doi-asserted-by":"crossref","first-page":"101704","DOI":"10.1016\/j.bjorl.2025.101704","article-title":"One-year efficacy of dupilumab in sense of smell, nasal polyp score and quality of life in CRSwNP patients: a real-world multicenter study in Brazil","volume":"91","author":"Mieli","year":"2025","journal-title":"Braz J Otorhinolaryngol"},{"issue":"11","key":"10.1016\/j.arbres.2026.04.008_bib1430","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1111\/all.16263","article-title":"Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years","volume":"79","author":"Huber","year":"2024","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1435","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1440","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/lary.32171","article-title":"Reduction of rescue treatment with dupilumab for chronic rhinosinusitis with nasal polyps in japan","volume":"135","author":"Yoshikawa","year":"2025","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1445","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaci.2024.10.016","article-title":"Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)","volume":"155","author":"Seys","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1450","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11882-025-01192-y","article-title":"Effect of dupilumab in CRSwNP sinonasal outcomes from real life studies: a systematic review with meta-analysis","volume":"25","author":"Rodriguez-Iglesias","year":"2025","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1455","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1460","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.07.001","article-title":"Efficacy of dupilumab for severe chronic rhinosinusitis with nasal polyps and asthma: a prospective study","volume":"133","author":"Tajiri","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1465","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/biomedicines13020501","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma-a multidisciplinary monocentric real-life study","volume":"13","author":"Fadda","year":"2025","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1470","doi-asserted-by":"crossref","first-page":"101024","DOI":"10.1016\/j.waojou.2024.101024","article-title":"Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: a step towards clinical remission","volume":"18","author":"Al-Ahmad","year":"2025","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.arbres.2026.04.008_bib1475","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12890-024-03139-x","article-title":"Outcomes of biological therapy in patients with severe asthma with chronic rhinosinusitis in Saudi Arabia: patients with nasal polyps versus those without nasal polyps","volume":"24","author":"Abuelhassan","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaip.2024.09.013","article-title":"Eosinophilia and adverse effects of dupilumab for respiratory indications: a real-world setting","volume":"13","author":"Li","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.arbres.2026.04.008_bib1485","article-title":"Dupilumab-induced blood eosinophilia in patients with chronic rhinosinusitis with nasal polyps: temporal trends and correlation with adverse events","author":"De Corso","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1490","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2025.01.040","article-title":"Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot","volume":"13","author":"Caminati","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1495","first-page":"386","article-title":"Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review","volume":"63","author":"Lazzeroni","year":"2025","journal-title":"Rhinology"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1500","first-page":"768","article-title":"Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm","volume":"63","author":"De Corso","year":"2025","journal-title":"Rhinology"},{"key":"10.1016\/j.arbres.2026.04.008_bib1505","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.arbres.2026.04.008_bib1510","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/JAA.S288260","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study","volume":"14","author":"Emson","year":"2021","journal-title":"J Asthma Allergy"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1515","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1007\/s12325-025-03231-6","article-title":"Effectiveness and safety of tezepelumab in a diverse population of us patients with severe asthma: initial results of the PASSAGE Study","volume":"42","author":"Lugogo","year":"2025","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1520","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2024.09.015","article-title":"Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison","volume":"12","author":"Hopkins","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1530","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy","volume":"14","author":"Papacharalampous","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1535","doi-asserted-by":"crossref","first-page":"419","DOI":"10.18176\/jiaci.0939","article-title":"Improvement in smell using monoclonal antibodies among patients with chronic rhinosinusitis with nasal polyps: a systematic review","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1540","doi-asserted-by":"crossref","first-page":"101633","DOI":"10.1016\/j.bjorl.2025.101633","article-title":"Long-term efficacy and safety of different biologics in treatment of chronic rhinosinusitis with nasal polyps: a network meta-analysis","volume":"91","author":"Chen","year":"2025","journal-title":"Braz J Otorhinolaryngol"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1545","first-page":"1455","article-title":"Optimizing biologic treatment selection in chronic rhinosinusitis with nasal polyps: a network meta-analysis of efficacy and safety across 22 RCTs","volume":"18","author":"Safia","year":"2025","journal-title":"Pharm (Basel)"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1555","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1007\/s00405-025-09725-x","article-title":"Early real-life outcomes of dupilumab and mepolizumab in patients with uncontrolled primary diffuse type 2 chronic rhinosinusitis","volume":"282","author":"Saccardo","year":"2025","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1560","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S2213-2600(25)00287-5","article-title":"Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial","volume":"13","author":"De Corso","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1565","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12890-025-03911-7","article-title":"Comparative efficacy of biologics for uncontrolled asthma patients with chronic rhinosinusitis or nasal polyps: a systematic review and network meta-analysis","volume":"25","author":"Tsukada","year":"2025","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1570","doi-asserted-by":"crossref","first-page":"100746","DOI":"10.1016\/j.waojou.2023.100746","article-title":"A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics","volume":"16","author":"F\u00f6rster-Ruhrmann","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1575","doi-asserted-by":"crossref","first-page":"e12049","DOI":"10.1002\/clt2.12049","article-title":"Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP","volume":"11","author":"M\u00fcmmler","year":"2021","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1580","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.jacig.2023.100174","article-title":"The effect of biologics in lung function and quality of life of patients with united airways disease: a systematic review","volume":"3","author":"Dom\u00ednguez-Ortega","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1585","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.jaip.2024.05.016","article-title":"Exploring definitions and predictors of response to biologics for severe asthma","volume":"12","author":"Scelo","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.arbres.2026.04.008_bib1590","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.04.008_bib1595","first-page":"1","article-title":"The current evidence regarding the efficacy of tezepelumab administered for asthma on T2-related comorbidities","author":"Tiotiu","year":"2025","journal-title":"Expert Rev Respir Med"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1600","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1610","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1615","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1620","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1625","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1635","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1640","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.anai.2023.06.017","article-title":"Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth","volume":"131","author":"Supron","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1645","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: a case series","volume":"9","author":"Martin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.arbres.2026.04.008_bib1650","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12890-020-01248-x","article-title":"Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study","volume":"20","author":"Numata","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1660","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1665","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1670","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am J Rhinol Allergy"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1675","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/19458924241298817","article-title":"Dupilumab treatment for aspirin-exacerbated respiratory disease in a real-world setting: impact on quality of life and healthcare utilization","volume":"39","author":"Mullur","year":"2025","journal-title":"Am J Rhinol Allergy"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1680","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1685","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1690","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2021.11.020","article-title":"Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Patel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1695","doi-asserted-by":"crossref","first-page":"2201335","DOI":"10.1183\/13993003.01335-2022","article-title":"Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease","volume":"61","author":"Schneider","year":"2023","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1700","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1705","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1710","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2025.03.033","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR","volume":"13","author":"Laidlaw","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10450","key":"10.1016\/j.arbres.2026.04.008_bib1715","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","article-title":"Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment","volume":"404","author":"Zuberbier","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1720","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2015.04.015","article-title":"Similar efficacy with omalizumab in chronic idiopathic\/spontaneous urticaria despite different background therapy","volume":"3","author":"Casale","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1725","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1730","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/jdv.14384","article-title":"Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria","volume":"31","author":"Finlay","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1735","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/all.14547","article-title":"Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1740","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","article-title":"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u201creal-world\u201d evidence","volume":"18","author":"Bernstein","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1745","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \u201creal-world\u201d evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1750","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/jdv.15045","article-title":"Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study","volume":"32","author":"Ghazanfar","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1755","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1760","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/ced\/llae145","article-title":"Prevalence of omalizumab-resistant chronic urticaria and real-world effectiveness of dupilumab in patients with omalizumab-refractory chronic urticaria: a single-centre experience","volume":"49","author":"Zhu","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1765","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/bjd\/ljae067","article-title":"Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial","volume":"191","author":"Altrichter","year":"2024","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1770","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","article-title":"Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study","volume":"155","author":"McLaren","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.arbres.2026.04.008_bib1775","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2025.06.014","article-title":"Exploring mepolizumab use in chronic spontaneous urticaria: an open-label, single-arm, exploratory study","volume":"13","author":"Phillipps","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1780","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2025.06.004","article-title":"Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: systematic review and network meta-analysis","volume":"156","author":"Chu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"10478","key":"10.1016\/j.arbres.2026.04.008_bib1785","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1790","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/17476348.2025.2600698","article-title":"What is the role of the IgE-mediated allergy in severe asthma?","volume":"20","author":"Muti","year":"2026","journal-title":"Expert Rev Respir Med"},{"issue":"24","key":"10.1016\/j.arbres.2026.04.008_bib1795","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.arbres.2026.04.008_bib1800","doi-asserted-by":"crossref","first-page":"e15588","DOI":"10.1111\/dth.15588","article-title":"A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis","volume":"35","author":"Napolitano","year":"2022","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1805","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","article-title":"A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy","volume":"35","author":"Paller","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1810","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1815","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1820","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","article-title":"Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis","volume":"9","author":"Boguniewicz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1825","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1007\/s12325-024-02998-4","article-title":"Dupilumab is efficacious in young children with atopic dermatitis regardless of type 2 comorbidities","volume":"41","author":"Boguniewicz","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1830","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1835","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5114\/ada.2018.77243","article-title":"The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry","volume":"35","author":"Hutyrov\u00e1","year":"2018","journal-title":"Adv Dermatol Allergol"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1840","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1845","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.1111\/jdv.19195","article-title":"Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial","volume":"37","author":"Guttman-Yassky","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1850","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.arbres.2026.04.008_bib1855","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/all.16620","article-title":"The evolution, immunopathogenesis and biomarkers of type 2 inflammation in common allergic disorders","volume":"80","author":"Gao","year":"2025","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1860","doi-asserted-by":"crossref","DOI":"10.1093\/cei\/uxaf039","article-title":"Unravelling the pathogenesis of eosinophilic esophagitis from genetic predisposition to environmental triggers","volume":"219","author":"Aziz","year":"2025","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1865","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1870","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1875","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/all.16046","article-title":"A randomized, double-blind placebo-controlled study on the efficacy of omalizumab on food allergy threshold in children with severe food allergy","volume":"79","author":"Mortz","year":"2024","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1880","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cea.12862","article-title":"Individually dosed omalizumab: an effective treatment for severe peanut allergy","volume":"47","author":"Brandstr\u00f6m","year":"2017","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.arbres.2026.04.008_bib1885","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1890","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1895","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2500\/aap.2010.31.3304","article-title":"Effects of omalizumab in patients with food allergy","volume":"31","author":"Rafi","year":"2010","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1900","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1905","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.arbres.2026.04.008_bib1910","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/JAA.S475517","article-title":"Does comorbid food allergy affect response to omalizumab in patients with asthma?","volume":"17","author":"Fiocchi","year":"2024","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1915","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/all.16404","article-title":"Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study","volume":"80","author":"Sindher","year":"2025","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1920","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/all.16420","article-title":"Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy","volume":"80","author":"Chinthrajah","year":"2025","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1925","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.arbres.2026.04.008_bib1930","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S2468-1253(23)00204-2","article-title":"Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"8","author":"Rothenberg","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"24","key":"10.1016\/j.arbres.2026.04.008_bib1935","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age","volume":"390","author":"Chehade","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.arbres.2026.04.008_bib1940","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.14309\/ajg.0000000000002924","article-title":"Dupilumab improves health-related quality of life and a range of symptoms in patients with eosinophilic esophagitis","volume":"119","author":"Spergel","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1945","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cgh.2023.08.015","article-title":"Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.arbres.2026.04.008_bib1950","doi-asserted-by":"crossref","first-page":"412","DOI":"10.18176\/jiaci.1011","article-title":"Concomitant efficacy of dupilumab in treating eosinophilic esophagitis and type 2 asthma","volume":"34","author":"Tom\u00e1s-P\u00e9rez","year":"2024","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1955","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","article-title":"Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE","volume":"147","author":"Clayton","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1960","doi-asserted-by":"crossref","first-page":"e0113483","DOI":"10.1371\/journal.pone.0113483","article-title":"A pilot study of omalizumab in eosinophilic esophagitis","volume":"10","author":"Loizou","year":"2015","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.arbres.2026.04.008_bib1965","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","article-title":"Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"72","author":"Dellon","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.arbres.2026.04.008_bib1970","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.arbres.2026.04.008_bib1975","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.arbres.2026.04.008_bib1980","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.arbres.2026.04.008_bib1985","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines \u2013 recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.arbres.2026.04.008_bib1990","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-024-00653-6","article-title":"Safety of biological therapies for severe asthma: an analysis of suspected adverse reactions reported in the WHO pharmacovigilance database","volume":"38","author":"Cutroneo","year":"2024","journal-title":"BioDrugs"},{"issue":"176","key":"10.1016\/j.arbres.2026.04.008_bib1995","doi-asserted-by":"crossref","first-page":"240269","DOI":"10.1183\/16000617.0269-2024","article-title":"Safety of biologics for the treatment of asthma in children and adolescents: a systematic review","volume":"34","author":"Wirthgen","year":"2025","journal-title":"Eur Respir Rev"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028962600150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028962600150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:19:08Z","timestamp":1778271548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030028962600150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":200,"alternative-id":["S030028962600150X"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2026.04.008","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Biologics Administered for Severe Asthma on T2-comorbidities: A Narrative Review","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}